

VU Research Portal

New insights into anti-TNF treatment of ankylosing spondylitis

de Vries, M.K.

2013

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

de Vries, M. K. (2013). *New insights into anti-TNF treatment of ankylosing spondylitis*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

Chapter 1 General Introduction

Section I Immunogenicity

Chapter 2

2.1 Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.

Annals of the Rheumatic Diseases 2007;66(1):133-134.

2.2 Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

Annals of the Rheumatic Diseases 2007;66(9):1252-1254.

Chapter 3

3.1 Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

Annals of the Rheumatic Diseases 2009;68(11):1787-1788.

3.2 Adalimumab in juvenile rheumatoid arthritis. Comment on the article by Lovell and colleagues.

New England Journal of Medicine 2008;359(23):2496.

Chapter 4 Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

Annals of the Rheumatic Diseases 2009;68(4):531-535.

Section II Biomarkers of disease activity and cardiovascular risk

Chapter 5

5.1 Erythrocyte sedimentation rate, C-reactive protein level and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

Arthritis and Rheumatism 2009;61(11):1484-1490.

5.2 C-reactive protein polymorphisms and haplotypes influence serum C-reactive protein levels independent of disease activity in ankylosing spondylitis.

Submitted

Chapter 6	
6.1	Discovertebral (Andersson) lesions of the spine in ankylosing spondylitis revisited. <i>Clinical Rheumatology 2009;28(8):883-892.</i>
6.2	Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography. <i>Clinical Rheumatology 2010;29(12):1433-1438.</i>
Chapter 7	Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism 2009;60(5):1324-1330.</i>
Section III	Extraspinal manifestations
Chapter 8	pANCA, ASCA, and OmpC antibodies are present in patients with ankylosing spondylitis without inflammatory bowel disease. <i>Journal of Rheumatology 2010;37(11):2340-2344.</i>
Chapter 9	The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology 2010;39(1):38-41.</i>
Chapter 10	General Discussion and Summary
Chapter 11	Nederlandse Samenvatting
Appendix	Questionnaires and BASMI Abbreviations List Dankwoord Curriculum Vitae